Request Trial
novartis-istock-641038488-photogearch-
photogearch / iStockphoto.com
29 June 2021PharmaAlex Baldwin

Novartis wants to claw back $209m in ‘overpayments’ to Genentech

Roche subsidiary  Genentech received $209.5 million in unnecessary payments from  Novartis Pharma for a patent licensing deal and is now refusing to return the payment, the Swiss pharma giant has alleged in a redacted complaint.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026   Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026   The decision leaves a $177 million verdict against Lilly intact, but a dissenting judge has warned the ruling could “undermine medical innovation” by allowing overly broad patent claims to survive and provide a way around the Supreme Court’s Amgen decision.
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026   Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

WATCH: LEO Pharma head of IP rights on doing more with less
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year
Roche, Marques counsel: The fight against ‘deadly’ counterfeits is a race for the newest and best tech
Fish & Richardson nets patent litigator to grow European practice
What's AI best at? In-house teams are still learning
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?